Ovarian cancer is a high-mortality malignancy in women. The contemporary clinical chemotherapy with classic cytotoxic drugs, targeted molecular inhibitors would mostly fail when ovarian cancer cells become drug-resistant or metastasize through the body or when patients bare no more toleration because of strong adverse effects. The past decade has spotted varying targeted delivery systems including antibody-drug conjugates (ADCs), peptide/folate/aptamer-drug conjugates, polymer-drug conjugates, ligand-functionalized nanomedicines, and dual-targeted nanomedicines that upgrade ovarian cancer chemo- and molecular therapy effectively in preclinical/clinical settings via endowing therapeutic agents selectivity and bypassing drug resistance as well as lessening systemic toxicity. The targeted delivery approaches further provide means to potentiate emergent treatment modalities such as molecular therapy, gene therapy, protein therapy, photodynamic therapy, dual-targeting therapy and combination therapy for ovarian cancer. This review highlights up-to-date development of targeted drug delivery strategies toward advanced, metastatic, relapsed, and drug resistant ovarian cancers.

卵巢癌是女性高死亡率的恶性肿瘤。当卵巢癌细胞产生耐药性或通过全身转移或患者因强烈的不良反应不再耐受时，现代临床化疗与经典的细胞毒药物、靶向分子抑制剂大多会失败。过去十年发现了不同的靶向递送系统，包括抗体-药物偶联物 (ADC)、肽/叶酸/适体-药物偶联物、聚合物-药物偶联物、配体功能化纳米药物，以及升级卵巢癌化学和分子生物学的双靶向纳米药物通过赋予治疗剂选择性和绕过耐药性以及减轻全身毒性，在临床前/临床环境中进行有效治疗。靶向递送方法进一步提供了增强紧急治疗方式的手段，例如卵巢癌的分子疗法、基因疗法、蛋白质疗法、光动力疗法、双靶向疗法和联合疗法。本综述重点介绍了针对晚期、转移性、复发性和耐药性卵巢癌的靶向给药策略的最新发展。